期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 11, 期 6, 页码 308-323出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2014.68
关键词
-
类别
资金
- Memorial Sloan-Kettering Cancer Center
- Sidney Kimmel Center for Prostate and Urologic Cancers
- MSKCC SPORE in Prostate Cancer [P50 CA92629]
- Department of Defense Prostate Cancer Research Program [PC051382, PC121111]
- Prostate Cancer Foundation
- University of California, San Francisco
- Helen Diller Family Cancer Center
- NRG Oncology
- University of California San Francisco Resource Allocation Program
- General Electric ISR
Approximately 15% of patients with prostate cancer are diagnosed with high-risk disease. However, the current definitions of high-risk prostate cancer include a heterogeneous group of patients with a range of prognoses. Some have the potential to progress to a lethal phenotype that can be fatal, while others can be cured with treatment of the primary tumour alone. The optimal management of this patient subgroup is evolving. A refined classification scheme is needed to enable the early and accurate identification of high-risk disease so that more-effective treatment paradigms can be developed. We discuss several principles established from clinical trials, and highlight other questions that remain unanswered. This Review critically evaluates the existing literature focused on defining the high-risk population, the management of patients with high-risk prostate cancer, and future directions to optimize care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据